Global Virtual Symposium on Liquid Biopsy
February 10, 2026
We are delighted to invite you to the Global Virtual Symposium on Liquid Biopsy, organized by Impact Research Communications, taking place online on February 10, 2026.
This virtual symposium serves as a premier forum for advancing the science and clinical translation of liquid biopsy, a field that is revolutionizing cancer care by providing non-invasive, real-time insights into tumor biology and guiding personalized treatment. Bringing together leading investigators, clinicians, and industry experts, the program emphasizes both fundamental discoveries and translational research that bridge basic biology with clinical application.
Sessions will explore the latest advances in circulating free DNA (cfDNA), circulating tumor DNA (ctDNA), microRNA, circulating tumor cells (CTCs), extracellular vesicles, proteins, and molecular pathways, highlighting progress in biomarker discovery, disease mechanisms, and precision oncology. Through invited lectures, scientific panels, and industry-led discussions, the symposium aims to foster interdisciplinary collaboration, critically address methodological and regulatory challenges, and accelerate the integration of liquid biopsy technologies into routine clinical practice to improve early detection, monitoring, and patient outcomes.
• Stay Ahead in Research: Learn from leading experts about the latest
breakthroughs in
cfDNA, ctDNA, circulating tumor cells (CTCs), and other cutting-edge liquid biopsy biomarkers from various
research groups.
• Flexible Learning: Access recorded sessions for 6
months, so you never miss insights.
• Connect & Collaborate: Network with research peers during breaks and interactive
virtual sessions.
• Affordable & Accessible: Join a world-class symposium without the costs or
hassle of
travel and accommodation.
Program Outline
February 10 2026, 0800 EST (US)
Opening Remarks by Chair
Importance of liquid biopsy in precision medicine
Scientific Sessions
LB1: Technology & Methodology
ctDNA detection technologies, cfDNA sequencing advances, exosomes & extracellular vesicles, multiomics
integration, quality control standards
Break / Networking Session (Virtual Breakout)
LB2: Clinical Applications & Translation
Early cancer detection, treatment monitoring, minimal residual disease, personalized therapy
selection
Break / Networking Session (Virtual Breakout)
LB13: Innovation, Industry & Future Directions
AI/ML integration, regulatory pathways, clinical trial design, emerging biomarkers beyond cancer
1600
Closing Remarks
